HALO | Halozyme therapeutics, inc. - Stock Value & PE Ratio Analysis

3

24

15

Excellent Growth

AI analysis rates HALO with the highest value score of 5.
It is mainly due to stable revenue growth, along with adequate operating cash flow.
Over the past 3 months, HALO has maintained a consecutive value rating of 5.0, slightly higher than the rating of 4.4 over the past 3 years, indicating continued upward trend in enterprise value.
Compared to all stocks in the Health Care sector, HALO has a higher value rating.

HALO Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/02/21 (Weekly Update)

HALO Financial Forecast

Unit : USD

Update to 2025/5/4 (Quarterly Update)

HALO Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	1.26	53.7%	7.7%	298.01M	29.5%	4.3%	47.2%
2024Q2	1.27	69.3%	29.6%	290.08M	34.3%	-0.9%	40.3%
2024Q1	0.91	23%	19.7%	231.35M	4.7%	10.7%	39.2%
2023Q4	0.79	68.1%	12.9%	195.88M	20.8%	-2%	37.1%
2023Q3	0.82	70.8%	0%	230.04M	26.7%	-0.5%	37.9%

Update to 2025/5/7 (Quarterly Update)

HALO Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

HALO Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of HALO from 2007/01 till Now

1293.60%
Cumulative Return: 15.49%
Annual Return: 35.91%
Volatility: 0.43
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to May, 2025. (Total Trades: 6)